- Home
- WEA vs ZNTL Comparison
WEA vs ZNTL Comparison
Compare WEA & ZNTL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- WEA
- ZNTL
- Stock Information
- Founded
- WEA 2002
- ZNTL 2014
- Country
- WEA United States
- ZNTL United States
- Employees
- WEA N/A
- ZNTL N/A
- Industry
- WEA Trusts Except Educational Religious and Charitable
- ZNTL Biotechnology: Pharmaceutical Preparations
- Sector
- WEA Finance
- ZNTL Health Care
- Exchange
- WEA Nasdaq
- ZNTL Nasdaq
- Market Cap
- WEA 129.0M
- ZNTL 105.8M
- IPO Year
- WEA N/A
- ZNTL 2020
- Fundamental
- Price
- WEA $10.89
- ZNTL $1.24
- Analyst Decision
- WEA
- ZNTL Buy
- Analyst Count
- WEA 0
- ZNTL 7
- Target Price
- WEA N/A
- ZNTL $8.60
- AVG Volume (30 Days)
- WEA 46.1K
- ZNTL 1.4M
- Earning Date
- WEA 01-01-0001
- ZNTL 08-08-2025
- Dividend Yield
- WEA 7.87%
- ZNTL N/A
- EPS Growth
- WEA N/A
- ZNTL N/A
- EPS
- WEA N/A
- ZNTL N/A
- Revenue
- WEA N/A
- ZNTL $26,865,000.00
- Revenue This Year
- WEA N/A
- ZNTL N/A
- Revenue Next Year
- WEA N/A
- ZNTL N/A
- P/E Ratio
- WEA N/A
- ZNTL N/A
- Revenue Growth
- WEA N/A
- ZNTL N/A
- 52 Week Low
- WEA $9.60
- ZNTL $1.01
- 52 Week High
- WEA $11.29
- ZNTL $5.44
- Technical
- Relative Strength Index (RSI)
- WEA 63.78
- ZNTL 44.51
- Support Level
- WEA $10.77
- ZNTL $1.13
- Resistance Level
- WEA $10.84
- ZNTL $1.39
- Average True Range (ATR)
- WEA 0.11
- ZNTL 0.12
- MACD
- WEA 0.01
- ZNTL -0.03
- Stochastic Oscillator
- WEA 57.29
- ZNTL 26.83
About WEA Western Asset Bond Fund Share of Beneficial Interest
Western Asset Premier Bond Fund is a diversified closed-end management investment company. Its investment objective is to provide current income and capital appreciation by investing in a diversified portfolio of investment-grade bonds. The Fund invests in sectors, such as financials, energy, telecommunication services, consumer discretionary, healthcare, materials, information technology, and consumer staples.
About ZNTL Zentalis Pharmaceuticals Inc.
Zentalis Pharmaceuticals Inc is a clinical-stage biopharmaceutical company developing azenosertib (ZN-c3), a potentially first-in-class and best-in-class WEE1 inhibitor for patients with Cyclin E1-positive platinum-resistant ovarian cancer (Cyclin E1+ PROC). The Company manages its operations as a single segment for the purposes of assessing performance and making operating decisions.